Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

PHASE3CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

June 30, 2021

Study Completion Date

June 30, 2021

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Rituximab

Rituximab SC 1400 mg

DRUG

Cyclophosphamide

Cyclophosphamide will be administered as per standard local practice.

DRUG

Doxorubicin

Doxorubicin will be administered as per standard local practice.

DRUG

Vincristine

Vincristine will be administered as per standard local practice.

DRUG

Prednisone

Prednisone will be administered as per standard local practice.

DRUG

Fludarabine

Fludarabine will be administered as per standard local practice.

Trial Locations (13)

1008

Aziza Othmana Hospital; Clinical Haematology, Tunis

Hopital Militaire d'instruction de Tunis; Service d'hématologie, Tunis

3025

CHU Hédi Chacker; Service d'hématologie, Sfax

4000

CHU Farhat Hached; Service d'hématologie, Sousse

5000

CHU Fattouma Bourguiba, Monastir; Service d'hématologie, Monastir

10090

Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique, Rabat

15000

Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie, Tizi Ouzou

20100

CHU 20 Aout Service D'Onco-Hematologie Pediatrique, Casablanca

20340

Clinique AlMadina; Service hematologie, Casablanca

23000

Hôpital Dorban CHU Annaba, Service d'Hématologie, Annaba

31000

EHU Oran, Service d'Hématologie et de Thérapie Cellulaire, Oran

40000

Centre Hospitalier Uni Ire de Marrakech; Oncologie-Hématologie, Marrakesh

09000

EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward, Blida

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02406092 - Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A | Biotech Hunter | Biotech Hunter